USC Norris Comprehensive Cancer Center - Keck School of Medicine

University of Southern California

Los Angeles, CA
Website
(888) 828-2206

Sorting 5 by

Accepting patients

EXCALIBER RRMM

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Iberdomide, Daratumumab and Dexamethasone VS Daratumumab, Bortezomib, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Learn more
  • CELMoD
  • Randomization
  • Phase 3

Accepting patients

Low-Dose Radiotherapy for Bone Metastases

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
Learn more
  • Radiation
  • Phase 2
Get personalized results in 60 seconds
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

AMBUSH

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
Learn more
  • Checkpoint Inhibitor
  • Reovirus
  • PD-1
  • Phase 2

Not yet accepting

BMF-219

A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)
Learn more
  • Menin Inhibitor
  • Phase 1

Not yet accepting

QXL138AM

A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma
Learn more
  • CD138
  • Phase 1